X0306 4 2019-04-23 1 0001302573 OncoMed Pharmaceuticals Inc OMED 0001270734 PAKIANATHAN DEEPIKA C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 1 0 0 0 Common Stock 2019-04-23 4 U 0 1991602 D 0 I By Delphi Ventures VIII, L.P. Common Stock 2019-04-23 4 U 0 18940 D 0 I By Delphi BioInvestments VIII, L.P. On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi VIII Funds"). As a managing member of DMP VIII, the Reporting Person shares voting and dispositive power over the shares held by the Delphi VIII Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi VIII Funds, except to the extent of her proportionate pecuniary interest therein. /s/ Alicia Hager, Attorney-in-Fact for Deepika R. Pakianathan 2019-04-23